To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
July 2022

SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression

Vol: 261| Issue: 1| Number:4| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-Controlled Trial

J Am Acad Orthop Surg Glob Res Rev . 2022 May 1;6(5).

Contributing Authors:
A Ekelund A Peredistijs J Grohs J Meisner N Verity S Rasmussen

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and seven patients undergoing an arthroscopic subacromial decompression (ASD) surgery were randomized (in a 2:1:1 ratio) to receive either sucrose acetate isobutyrate extended-release (SABER) bupivacaine (n=53), SABER-placebo (n=25), or bupivacaine HCl (n=29) to minimize post-operative pain and opioid consumption. The primary outcomes of this trial were to assess pain scores and analge...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue